

Table I-18
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2001^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			26-Year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
All Sites	3,765,929	3,839,441	4,120,783	9,048,822	9,220,361
Male	1,898,532	1,924,231	2,057,870	4,163,637	4,212,021
Female	1,867,397	1,915,210	2,062,913	4,885,185	5,008,340
Oral Cavity & Pharynx	82,674	93,488	95,948	206,494	224,986
Male	55,409	62,109	63,607	133,057	143,709
Female	27,265	31,379	32,341	73,437	81,277
Esophagus	15,737	18,638	18,650	22,081	25,810
Male	11,952	13,945	13,945	16,515	19,027
Female	3,785	4,693	4,705	5,566	6,783
Stomach	29,431	34,023	34,105	55,827	62,559
Male	17,724	20,593	20,627	32,088	36,017
Female	11,707	13,430	13,478	23,739	26,542
Colon & Rectum	403,032	460,916	468,964	968,947	1,070,487
Male	201,690	231,008	234,709	471,439	517,261
Female	201,342	229,908	234,255	497,508	553,226
Liver & Intrahep	10,956	12,582	12,593	14,108	15,944
Male	7,118	8,193	8,204	8,706	9,905
Female	3,838	4,389	4,389	5,402	6,039
Pancreas	18,095	21,156	21,156	23,967	27,543
Male	8,680	10,372	10,372	11,163	13,073
Female	9,415	10,784	10,784	12,804	14,470
Larynx	34,076	39,252	39,432	92,464	101,321
Male	26,759	30,913	31,046	74,006	80,900
Female	7,317	8,339	8,386	18,458	20,421
Lung & Bronchus	201,687	243,497	247,320	330,991	388,538
Male	101,771	123,706	125,522	165,394	193,505
Female	99,916	119,791	121,798	165,597	195,033
Melanoma of the Skin	194,560	214,066	219,641	544,920	578,885
Male	103,566	115,336	118,977	269,150	287,927
Female	90,994	98,730	100,664	275,770	290,958
Breast					
Female	791,033	846,865	880,990	2,058,593	2,184,125
Cervix					
Female	46,131	48,226	48,288	174,429	179,437
Corpus & Uterus					
Female	140,432	157,422	157,475	474,773	510,266

^a US 2001 cancer prevalence counts are based on 2001 cancer prevalence proportions from the SEER 9 registries and 1/1/2001 US population estimates based on the average of 2000 and 2001 population estimates from the US Bureau of the Census.

^{bcd} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1975-2000); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1996-2000). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence.

In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table I-18 - continued
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2001^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			26-Year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 26 Years ^d
Ovary					
Female	53,367	61,207	61,212	137,976	153,863
Prostate					
Male	854,021	920,213	920,281	1,721,366	1,838,653
Testis					
Male	36,654	37,256	37,808	136,928	138,606
Urinary Bladder					
Male	182,170	217,670	218,962	460,530	521,945
Female	136,806	163,071	164,170	341,794	385,549
Female	45,364	54,599	54,792	118,736	136,396
Kidney & Renal Pelvis					
Male	85,215	102,069	102,742	196,981	225,128
Female	51,234	62,053	62,545	116,559	133,919
Female	33,981	40,016	40,197	80,422	91,209
Brain & Nervous System					
Male	34,921	36,642	36,751	87,853	90,304
Female	19,339	20,344	20,376	47,814	49,141
Female	15,582	16,298	16,375	40,039	41,163
Thyroid					
Male	82,780	88,485	88,667	261,607	273,642
Female	19,086	20,927	20,976	59,817	63,033
Female	63,694	67,558	67,691	201,790	210,609
Hodgkin Lymphoma					
Male	33,445	34,715	34,726	120,684	123,181
Female	17,766	18,435	18,435	62,988	64,279
Female	15,679	16,280	16,291	57,696	58,902
Non-Hodgkin Lymphoma					
Male	149,775	169,517	169,968	316,297	346,749
Female	78,674	89,136	89,398	163,797	178,734
Female	71,101	80,381	80,570	152,500	168,015
Myeloma					
Male	34,489	39,418	39,430	48,987	54,930
Female	18,725	21,516	21,528	26,710	30,013
Female	15,764	17,902	17,902	22,277	24,917
Leukemia					
Male	76,511	85,522	85,546	173,859	187,285
Female	43,969	49,297	49,309	97,991	105,642
Female	32,542	36,225	36,237	75,868	81,643
Acute Lymphocytic Leuk					
Male	13,506	13,685	13,685	42,330	42,610
Female	7,536	7,633	7,633	23,174	23,304
Female	5,970	6,052	6,052	19,156	19,306
Childhood (0-19)					
Male	54,418	54,527	54,800	204,131	204,569
Female	28,817	28,871	29,025	104,636	104,829
Female	25,601	25,656	25,775	99,495	99,740

^a US 2001 cancer prevalence counts are based on 2001 cancer prevalence proportions from the SEER 9 registries and 1/1/2001 US population estimates based on the average of 2000 and 2001 population estimates from the US Bureau of the Census.

^{bcde} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 26 years (1975-2000); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1996-2000). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 26-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 26-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 26-year limited duration prevalence.

In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.